Niagen Bioscience, Inc. — Director's Dealing 2018

Jun 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2018-06-22

Reporting Person: Fried Robert N (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-22	Common Stock	A	166667	—	Acquired	1093241	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-22	Stock Option (right to buy)	$3.83	A	744097	Acquired	2028-06-22	Common Stock (744097)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12744	Indirect

Footnotes

F1: These fully-vested shares are awarded to Mr. Fried pursuant to the achievement of the performance criteria detailed in his Executive Employment Agreement, dated March 12, 2017, as amended.

F2: 6,744 shares held by Jeremy Fried and 6,000 shares held by Benjamin Fried, who are both sons of Robert Fried.

F3: Awarded pursuant to his Amended and Restated Executive Employment Agreement dated June 22, 2018, in consideration of his appointment by the Board to CEO.

F4: 1/3rd of the shares vest on June 22, 2019 and the remaining shares vest in a series of 24 equal monthly installments thereafter.